Kercheville Advisors LLC Has $4.11 Million Stake in Eli Lilly and Company $LLY

Kercheville Advisors LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 98.3% in the fourth quarter, HoldingsChannel reports. The firm owned 3,776 shares of the company’s stock after purchasing an additional 1,872 shares during the period. Eli Lilly and Company makes up approximately 1.2% of Kercheville Advisors LLC’s investment portfolio, making the stock its 27th biggest holding. Kercheville Advisors LLC’s holdings in Eli Lilly and Company were worth $4,106,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the company. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC boosted its position in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares in the last quarter. 10Elms LLP boosted its position in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 10 shares in the last quarter. Miller Global Investments LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $33,000. Finally, Hopwood Financial Services Inc. boosted its position in Eli Lilly and Company by 113.6% in the third quarter. Hopwood Financial Services Inc. now owns 47 shares of the company’s stock valued at $36,000 after buying an additional 25 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on LLY shares. TD Cowen boosted their price objective on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. Royal Bank Of Canada started coverage on Eli Lilly and Company in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price objective on the stock. Loop Capital set a $1,200.00 price objective on Eli Lilly and Company in a research note on Tuesday, February 10th. Argus boosted their price objective on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,216.52.

Eli Lilly and Company Trading Up 0.7%

LLY stock opened at $874.14 on Wednesday. The company has a market cap of $825.91 billion, a P/E ratio of 38.09, a PEG ratio of 1.03 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The business has a fifty day moving average of $952.17 and a 200-day moving average of $986.25.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm’s quarterly revenue was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 33.9 EPS for the current year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Acquisition — Lilly agreed to buy Ajax Therapeutics for up to $2.3 billion, adding a Type II JAK2 inhibitor for myelofibrosis and expanding its hematology/oncology pipeline. Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion
• Positive Sentiment: AI drug‑discovery partnership — Lilly struck a deal with AI startup Profluent (reported as up to $2.25 billion), signaling investment in AI-enabled discovery that could accelerate new programs and cost efficiency. Emeryville AI Upstart Snags $2.25 Billion Gene Editing Deal With Eli Lilly
• Positive Sentiment: Analyst support — Multiple analysts and outlets have reiterated bullish views (e.g., Barclays Overweight with a $1,350 target), supporting the narrative that Lilly’s deal cadence and diversified pipeline justify higher valuation. Analysts Reiterate Bullish Outlook on Eli Lilly and Company (LLY) Following Kelonia Acquisition
• Neutral Sentiment: Sector tone — Health‑care stocks broadly edged higher midday, providing modest tailwinds for large-cap pharma names including LLY. Sector Update: Health Care Stocks Edge Higher Late Afternoon
• Neutral Sentiment: Near‑term earnings focus — Analysts are parsing Q1 guidance and launch metrics ahead of results; market reaction may hinge on GLP‑1 trends and margins. Countdown to Lilly (LLY) Q1 Earnings: Wall Street Forecasts for Key Metrics
• Negative Sentiment: GLP‑1 competitive pressure — Data and prescription tracking show Novo Nordisk’s oral Wegovy gaining share vs. Lilly’s oral competitor, raising concerns about Foundayo adoption and near‑term revenue growth. GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival
• Negative Sentiment: New competitor data — A late‑stage obesity trial from Boehringer/Ingelheim showed meaningful weight loss, intensifying competition in the obesity space where Lilly has been a market leader. Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
• Negative Sentiment: Short‑term pullback/volatility — Shares pulled back with the broader market ahead of earnings as investors weigh pricing pressure, rising costs and softer launch datapoints. Pharmaceutical Stock Pulling Back Before Earnings

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.